Anakinra in the treatment of rheumatic disease

References

• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344(12), 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Saxne T, Palladino MA Jr, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum.31(8), 1041–1045 (1988).
   PubMed Web of Science ®Google Scholar
• Houssiau FA. Cytokines in rheumatoid arthritis. Clin. Rheumatol.14(Suppl. 2).10–13 (1995).
   PubMedGoogle Scholar
• Mitchell D. Epidemiology. In: Rheumatoid Arthritis: Etiology, Diagnosis, Management. Utsinger P, Zvaifler N, Ehrlich G (Ed.). JB Lippincott, Philadelphia, PA, USA, 133–137 (1985).
   Google Scholar
• Robinson H. Multidisciplinary ambulatory care for the elderly arthritis patient. In: Arthritis and the Elderly. Moskowitz H, Haug M (Eds). Springer, New York, USA, 146–149 (1986).
   Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature423(6937), 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics.22(Suppl. 2), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Linos A, Worthington JW, O’Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am. J. Epidemiol.111(1), 87–98 (1980).
   PubMed Web of Science ®Google Scholar
• MacGregor AJ, Silman AJ. Classification and epidemiology. In: Rheumatology. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Elsevier Science, Phildelphia, PA, USA, 757–763 (2003).
   Google Scholar
• Lawrence RC, Helmick CG, Arnett FC et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum.41(5), 778–799 (1998).
   PubMed Web of Science ®Google Scholar
• Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J. Rheumatol.13(5), 899–902 (1986).
   PubMed Web of Science ®Google Scholar
• Silman AJ, MacGregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol.32(10), 903–907 (1993).
   PubMedGoogle Scholar
• Albers JM, Kuper HH, Van Riel PL et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford)38(5), 423–430 (1999).
   PubMed Web of Science ®Google Scholar
• Birnbaum HG, Barton M, Greenberg PE et al. Direct and indirect costs of rheumatoid arthritis to an employer. J. Occup. Environ. Med.42(6), 588–596 (2000).
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum.48(10), 2750–2762 (2003).
   PubMed Web of Science ®Google Scholar
• Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am. Fam. Physician72(6), 1037–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum.42(6), 1209–1218 (1999).
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Cox N et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford)39(6), 603–611 (2000).
   PubMed Web of Science ®Google Scholar
• Young A, Dixey J, Kulinskaya E et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann. Rheum. Dis.61(4), 335–340 (2002).
   PubMed Web of Science ®Google Scholar
• Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J. Occup. Environ. Med.48(2), 135–148 (2006).
   PubMed Web of Science ®Google Scholar
• O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med.350(25), 2591–2602 (2004).
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum.54(1), 26–37 (2006).
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde DM, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.Lancet363(9410), 675–681 (2004).
   PubMed Web of Science ®Google Scholar
• St Clair EW, van der Heijde DM, Smolen J et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum.50(11), 3432–3443 (2004).
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med.343(22), 1586–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum.52(11), 3381–3390 (2005).
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.Lancet364(9430), 263–269 (2004).
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, Landewe R, Keystone E, Van Riel PL, Sasso E, Perez J. Adalimumab (HUMIRA®) plus MTX prevents nearly all severe radiographic progression observed with methotrexate monotherapy in early, aggressive rheumatoid arthritis. Arthritis Rheum.52(Suppl. 9), (2005) (Abstract 207).
   Google Scholar
• van der Heijde DM, Klareskog L, Wajdula J, Pedersen R, Fatenejad S. Three years of sustained halting of radiographic progression with combination etanercept and methotrexate: results from the TEMPO Trial. Arthritis Rheum.52(Suppl. 9), L10–L14 (2005) (Abstract).
   Google Scholar
• van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, Van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum.39(1), 34–40 (1996).
   PubMed Web of Science ®Google Scholar
• van Gestel AM, Haagsma CJ, Van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum.41(10), 1845–1850 (1998).
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Unkerskov J, Krough NS et al. Poor remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept – results from the nationwide Danish “DANBIO” database. Ann. Rheum. Dis.64(Suppl. III), OP0011 (2005).
   Google Scholar
• Cohen S, Greenwald M, Dougados M et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF-α therapies (REFLEX Study). Arthritis Rheum.52(Suppl. 9), (2005) (Abstract 1839).
   Google Scholar
• Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N. Engl. J. Med.353(11), 1114–1123 (2005).
   PubMed Web of Science ®Google Scholar
• Weaver A, Lautzenheiser RL, Schiff MH et al. Effectiveness of biologics and disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: real-world outcomes from the RADIUS observational registry. Arthritis Rheum.52(Suppl. 9), (2005) (Abstract 1947).
   PubMedGoogle Scholar
• Genovese MC, Cohen S, Moreland L et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum.50(5), 1412–1419 (2004).
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Combe B, White A, Aranda R, Becker J, Keystone E. Safety of abatacept in patients with active rheumatoid arthritis receiving background non-biologic and biologic DMARDs: 1 year results of the ASSURE trial. Ann. Rheum. Dis.64(Suppl. III [Op0012]), 60 (2005).
   Google Scholar
• de Koning HD, Bodar EJ, Simon A, van der Hilst JC, Netea MG, van der Meer JW. Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann. Rheum. Dis.65(4), 542–524 (2005).
   PubMedGoogle Scholar
• Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum.52(6), 1794–1803 (2005).
   PubMed Web of Science ®Google Scholar
• Frenkel J, Wulffraat NM, Kuis W. Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum.50(11), 3738–3739 (2004).
   PubMed Web of Science ®Google Scholar
• Kallinich T, Hoffman HM, Roth J, Keitzer R. The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand. J. Rheumatol.34(3), 246–249 (2005).
   PubMed Web of Science ®Google Scholar
• Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum.33(3), 305–315 (1990).
   PubMed Web of Science ®Google Scholar
• Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford)42(Suppl. 2), ii3–ii10 (2003)
   PubMedGoogle Scholar
• Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med.322(18), 1277–1289 (1990).
   PubMed Web of Science ®Google Scholar
• Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J. Investig. Med.43(1), 28–38 (1995).
   PubMed Web of Science ®Google Scholar
• Gabay C, Arend WP. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin. Immunopathol.20(1–2), 229–246 (1998).
   PubMedGoogle Scholar
• Firestein GS, varo-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol.144(9), 3347–3353 (1990).
   PubMed Web of Science ®Google Scholar
• Chu CQ, Field M, Allard S, Abney E, Feldmann M, Maini RN. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br. J. Rheumatol.31(10), 653–661 (1992).
   PubMedGoogle Scholar
• Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford)42(Suppl. 2), ii11–ii16 (2003).
   PubMedGoogle Scholar
• Evans RJ, Bray J, Childs JD et al. Mapping receptor binding sites in interleukin (IL)-1 receptor antagonist and IL-1 β by site-directed mutagenesis. Identification of a single site in IL-1Ra and two sites in IL-1 β. J. Biol. Chem.270(19), 11477–11483 (1995).
   PubMedGoogle Scholar
• Hannum CH, Wilcox CJ, Arend WP et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature343(6256), 336–340 (1990).
   PubMed Web of Science ®Google Scholar
• Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR. A urine inhibitor of interleukin-1 activity that blocks ligand binding. J. Immunol.139(5), 1546–1549 (1987).
   PubMed Web of Science ®Google Scholar
• Eisenberg SP, Evans RJ, Arend WP et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature343(6256), 341–346 (1990).
   PubMed Web of Science ®Google Scholar
• Kineret In: Physician’s Desk Reference. Thomson, Montvale, USA, 594–596 (2006).
   Google Scholar
• Yang BB, Baughman S, Sullivan JT. Pharmacokinetics of anakinra in subjects with different levels of renal function. Clin. Pharmacol. Ther.74(1), 85–94 (2003).
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.41(12), 2196–2204 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(3), 614–624 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis.63(9), 1062–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum.48(4), 927–934 (2003).
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum.23(2), 137–145 (1980)
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum.38(6), 727–735 (1995).
   PubMed Web of Science ®Google Scholar
• Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J. Rheumatol.20, 557–560 (1993).
   PubMed Web of Science ®Google Scholar
• Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. Diagn. (Stockh.)18(4), 481–491 (1977).
   PubMed Web of Science ®Google Scholar
• Jiang Y, Genant H, Watt I, Cobby M, Bresnihan B, Aitchison R. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum.43, 1001–1009 (2000).
   PubMed Web of Science ®Google Scholar
• Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist).in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum.46(11), 2838–2846 (2002).
   PubMed Web of Science ®Google Scholar
• Shergy W, Cohen S, Greenwald M et al. Anakinra (Kineret®) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Arthritis Rheum.46(Suppl. 9), LB 10 (2002) (Abstract).
   PubMedGoogle Scholar
• Cohen SB, Woolley JM, Chan W. interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol.30(2), 225–231 (2003).
   PubMed Web of Science ®Google Scholar
• Chevrel G, Garnero P, Mirosses P. Combination of TNFα soluble receptors (sR) with IL-1 and IL-17 sR is more effective to reduce in vitro inflammation response of synoviocytes stimulated with RA PBMC supernatants. Arthritis Rheum.43(Suppl. 9) (2000) (Abstract 127).
   Google Scholar
• Rooney T, Madigan A, Greenan L et al. Combination therapy with anakinra and PEGylated soluble tumor necrosis factor type I (Pegsunercept).in rheumatoid arthritis (RA): preliminary analysis of clinical, functional, synovial tissue and radiographic outcomes from a phase II, open-label, mode of action study. Arthritis Rheum.48(Suppl. 9) (2003) (Abstract 211).
   PubMedGoogle Scholar
• Vasques Godinho FM, Parreira Santos MJ, Canas da SJ. Refractory adult onset Still’s disease successfully treated with anakinra. Ann. Rheum. Dis.64(4), 647–648 (2005).
   PubMed Web of Science ®Google Scholar
• Verbsky JW, White AJ. Effective use of the recombinant interleukin-1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol.31(10), 2071–2075 (2004).
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med.201(9), 1479–1486 (2005).
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum.46(12), 3340–3348 (2002).
   PubMed Web of Science ®Google Scholar
• Wang L, Manji GA, Grenier JM et al. PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κ B and caspase-1-dependent cytokine processing. J. Biol. Chem.277(33), 29874–29880 (2002).
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum.52(4), 1283–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford)44(5), 689–690 (2005).
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum.50(8), 2708–2709 (2004).
   PubMedGoogle Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum.50(2), 607–612 (2004).
   PubMed Web of Science ®Google Scholar
• Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus13(8), 605–606 (2004).
   PubMed Web of Science ®Google Scholar
• Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin-1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann. Rheum. Dis.64(4), 630–633 (2005).
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O’Connor P, Fraser A, Emery P, McGonagle D. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann. Rheum. Dis.63(9), 1041–1045 (2004).
   PubMed Web of Science ®Google Scholar
• Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J. Rheumatol.21(12), 2281–2285 (1994).
   PubMed Web of Science ®Google Scholar
• Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol.21(12), 2286–2291 (1994).
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis.64(2), 296–298 (2005).
   PubMed Web of Science ®Google Scholar
• Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J. Rheumatol.21(9), 1694–1698 (1994).
   PubMed Web of Science ®Google Scholar
• Anderson JJ, Baron G, Van Der HD, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum.44(8), 1876–1886 (2001).
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol.31(6), 1103–1111 (2004).
   PubMed Web of Science ®Google Scholar
• Schiff MH, DiVittorio G, Tesser J et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum.50(6), 1752–1760 (2004).
   PubMedGoogle Scholar
• Tesser J, Fleischmann R, Dore R et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin-1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol.31(4), 649–654 (2004).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Tesser J, Schiff M et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) (Epub ahead of print).
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER). Program Public-Use Data (1973–1999).[11 Registries, 1992–1999]. DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission 2002 (2006).
   Google Scholar
• Buch MH, Bingham SJ, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum.50(3), 725–728 (2004).
   PubMed Web of Science ®Google Scholar
• Saxne T, Larsson L, Geborek P. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. Arthritis Rheum.50(9), 3049–3050 (2004).
   PubMedGoogle Scholar
• Reiff A. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep.7(6), 434–440 (2005).
   PubMedGoogle Scholar
• Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum.40(7), 1202–1209 (1997).
   PubMed Web of Science ®Google Scholar
• Fleischmann RM. Examining the efficacy of biologic therapy: are there real differences? J. Rheumatol.65, 27–32 (2002).
   Google Scholar